NIBC brings Advicenne to Euronext Paris

NIBC is pleased to announce the successful completion of the Initial Public Offering (IPO) of pharmaceutical company Advicenne on Euronext Paris. Advicenne raised EUR 28.1 million which will enable the commercial launch of its lead drug, ADV7103 in Europe for the treatment of distal Renal Tubular Acidosis (dRTA), a pediatric kidney disease, including the finalization of phase III clinical trials in the United States.

NIBC acted as joint global coordinator, joint lead manager and joint bookrunner in this landmark transaction. With this transaction, our Life Sciences sector team achieved an important milestone and paves the way for many more capital market transactions to come. The success of this  Equity and Capital Markets transaction reflects NIBC´s approach of serving its clients with inventive tailor made advisory and financing solutions and contributes to our growth ambitions.

Advicenne is a late-stage pharmaceutical company focusing on the development of pediatric-friendly therapeutics for the treatment of orphan renal and neurological diseases. The Company’s most advanced product is ADV7103 which has shown positive results in a pivotal phase III study in children and adults with distal Renal Tubular Acidosis (dRTA). ADV7103 is also being developed in a second indication for the treatment of Cystinuria, an inherited renal tubulopathy and is expected to begin a pivotal phase III clinical trial in this indication in Europe in 2018.